Physician profile
Amanda Medley
NPI 1538620356
$14,007.27
in general payments reported to CMS, 2019-2025
27 companies · $2,046 in 2025
The $2,046 reported for 2025 was more than what 92% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,416 · 2022: $2,218 · 2023: $3,189 · 2024: $5,139 · 2025: $2,046.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,478 · Honoraria: $1,650 · Travel and Lodging: $1,240 · Education: $5.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,478.22 |
| Honoraria | $1,650.00 |
| Travel and Lodging | $1,240.03 |
| Education | $5.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $4,806.51 | 2021-2025 | Qelbree, Qelbree |
| Abbvie INC. | $1,213.70 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $938.54 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Corium, LLC | $932.69 | 2021-2025 | Azstarys |
| Vanda Pharmaceuticals INC. | $878.42 | 2021-2025 | Fanapt, Hetlioz |
| Lundbeck LLC | $812.98 | 2021-2025 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $802.60 | 2022-2025 | Austedo Xr, Austedo, Uzedy |
| Alkermes, INC. | $797.01 | 2021-2025 | Aristada, Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $618.84 | 2021-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $363.99 | 2021-2023 | Trintellix |
| Sunovion Pharmaceuticals INC. | $321.99 | 2021-2022 | |
| Axsome Therapeutics, INC. | $215.36 | 2022-2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $200.53 | 2021-2025 | Spravato |
| E.R. Squibb & Sons, L.L.C. | $161.75 | 2025 | Cobenfy |
| Indivior INC. | $159.37 | 2021-2024 | Sublocade, Perseris |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $158.42 | 2022-2025 | Ingrezza |
| Ironshore Pharmaceuticals INC. | $111.97 | 2022-2024 | Jornay Pm |
| Noven Therapeutics, LLC | $96.88 | 2024-2025 | Xelstrym |
| Uswm, LLC | $92.93 | 2022-2023 | Lucemyra, Zimhi |
| Tris Pharma INC | $90.14 | 2021-2023 | Dyanavel Xr |
| Biogen, INC. | $80.20 | 2025 | Zurzuvae |
| Idorsia Pharmaceuticals US INC | $52.49 | 2023 | Quviviq |
| Neuronetics, INC. | $28.86 | 2025 | Neurostar Tms Therapy System |
| Bausch Health US, LLC | $23.65 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $16.24 | 2025 | Rejoyn |
| Gilead Sciences, INC. | $15.86 | 2022 | |
| Bioventus LLC | $15.35 | 2025 | Durolane |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Medley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.